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Abstract
Objective: The Growth Hormone (GH) Research Society (GRS) convened a workshop to address important issues 
regarding trial design, efficacy, and safety of long-acting growth hormone preparations (LAGH).
Participants: A closed meeting of 55 international scientists with expertise in GH, including pediatric and adult 
endocrinologists, basic scientists, regulatory scientists, and participants from the pharmaceutical industry.
Evidence: Current literature was reviewed for gaps in knowledge. Expert opinion was used to suggest studies required 
to address potential safety and efficacy issues.
Consensus process: Following plenary presentations summarizing the literature, breakout groups discussed questions 
framed by the planning committee. Attendees reconvened after each breakout session to share group reports.  
A writing team compiled the breakout session reports into a draft document that was discussed and revised in 
an open forum on the concluding day. This was edited further and then circulated to attendees from academic 
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institutions for review after the meeting. Participants from pharmaceutical companies did not participate in the 
planning, writing, or in the discussions and text revision on the final day of the workshop. Scientists from industry and 
regulatory agencies reviewed the manuscript to identify any factual errors.
Conclusions: LAGH compounds may represent an advance over daily GH injections because of increased convenience 
and differing phamacodynamic properties, providing the potential for improved adherence and outcomes. Better 
methods to assess adherence must be developed and validated. Long-term surveillance registries that include 
assessment of efficacy, cost-benefit, disease burden, quality of life, and safety are essential for understanding the 
impact of sustained exposure to LAGH preparations.
Background
The long-term safety and efficacy of daily recombinant 
human growth hormone (rhGH) have been well 
documented since its approval by the United States 
Food and Drug Administration (FDA) in 1985 and by the 
European Medicines Agency (EMA) in 1987. However, 
daily GH injections can be burdensome for some patients 
and caregivers. Furthermore, variability in clinical 
outcomes is well recognized in clinical practice, and may 
reflect differences in adherence to prescribed therapy (1). 
Published data and clinical experience indicate that 
nonadherence to daily rhGH therapy increases over time 
(2, 3, 4, 5, 6, 7, 8) and impairs therapeutic responses. Many 
life circumstances can interfere with adherence to daily 
injections, thus compromising therapeutic outcomes. 
By decreasing injection frequency, long-acting GH (LAGH) 
formulations may improve adherence and thereby 
potentially maximize clinical efficacy. Consequently, 
there are currently several LAGH preparations in various 
stages of preclinical development, with some already 
approved for clinical use (Table 1).
In light of the interest generated by these new 
formulations, the Growth Hormone Research Society 
(GRS) convened a workshop in Asilomar, CA, USA on 
4–7 November 2015. The purpose of the workshop was 
to review the current state of the field and address key 
issues regarding trial design, efficacy, and safety of LAGH 
preparations.
Methods
Fifty-five invited international leaders from 14 countries 
across 5 continents with expertise in the field of GH 
attended the meeting. These included pediatric and 
adult endocrinologists, basic scientists, regulatory 
scientists from the FDA and EMA, and scientists from the 
pharmaceutical industry. A review of the current status of 
LAGH development was published before the meeting (9). 
A planning committee of the GRS comprising adult and 
pediatric endocrinologists from academic institutions 
determined the agenda, selected speakers to summarize 
key relevant topics, and formulated the questions for 
discussion at this workshop.
Following presentations that summarized the 
literature, four breakout groups addressed each topic in 
more detail by discussing the list of questions formulated 
by the planning committee and subsequently agreed 
upon by all participants. All attendees reconvened 
after each of the breakout sessions to share reports 
from the groups. At the end of days 1 and 2, a writing 
team compiled the breakout group reports into a 
final document that was reviewed and revised in its 
entirety by participants on the concluding day in an 
open forum. When there was no clear agreement by 
most participants, consensus was reached by voting. 
This draft document was edited further for formatting 
and references, and then recirculated to the academic 
attendees for final review after the meeting. Meeting 
participants from pharmaceutical companies were not 
part of the planning committee or writing team and 
were not present during the discussion and text revision 
on the final day. However, scientists from industry and 
regulatory agencies were shown the manuscript before 
submission in order to identify factual errors, but they 
were not involved in the writing. This report is a concise 
chronicle of the workshop and is not intended to be an 
exhaustive review of the literature on the topic. The 
contents of this manuscript were derived from: (i) the 
content of the speaker presentations, (ii) the combined 
comments of the breakout groups to the specific 
questions discussed, (iii) the collective remarks of the 
entire group during report-back sessions, and (iv) the 
current peer-reviewed literature in the GH field.
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The clinical need for a LAGH preparation in 
pediatric and adult endocrinology
Large interindividual variability in the growth response to 
daily GH injections in GH-deficient children and adults 
reflects numerous inherent biological factors, including 
dosing and dose frequency and varying sensitivity to 
both exogenous GH and endogenous insulin-like growth 
factor 1 (IGF1) (10, 11). In addition, reduced adherence to 
daily injections likely compromises response to treatment. 
The requirement for daily injections may also represent 
a barrier to initiating and maintaining therapy in both 
pediatric and adult patients. Many scenarios were discussed 
in which LAGH would represent a significant innovation 
in the delivery of clinical care for patients deficient in GH. 
All participants recognized the need for LAGH.
Development of LAGH preparations
As described in the review prepared for this workshop (9), 
several technologies are being used to prolong GH exposure. 
These include: (i) depot formulations, (ii) pegylation, 
(iii) prodrugs, (iv) noncovalent albumin binding GH 
compound(s), and (v) GH-fusion proteins (Table 1). These 
preparations are currently in various stages of development, 
with some already approved in Europe and Asia.
Endocrine features of LAGH
There was overall consensus that currently available 
data do not allow determination of whether the effects 
of LAGH will differ from those of daily GH. In addition, 
it is not clear whether the physiological GH pulsatility 
and diurnal secretory pattern seen in normal subjects are 
important for attaining optimal injected GH effects (12). 
It has been emphasized that many currently prescribed 
hormone replacement therapies, including daily GH, 
glucocorticoids, and various formulations of sex steroids, 
do not replicate normal physiologic pattern of secretion 
of the endogenous hormones in terms of pulsatility and 
diurnal variation. The LAGH preparations that were used 
in clinical trials, as well as continuous infusions of GH, 
did not result in tachyphylaxis or substantial differences 
in clinical effects when compared with daily injections of 
GH (13, 14, 15, 16).
Safety considerations unique to LAGH
LAGH products exhibit different pharmacokinetics 
and pharmacodynamics compared with daily GH and, 
therefore, safety considerations may be specific to these 
formulations. In particular, the mechanism whereby 
each product prolongs the action of GH differs; such 
additional moieties or properties may have an impact 
on safety distinct from considerations about GH or 
IGF1 levels. Therefore, the safety of each individual 
LAGH product should be assessed. Also, there is a need 
to consider the pharmacodynamic impact of each LAGH 
product. Care should be taken to avoid overtreatment, 
and therefore safety monitoring is critically important. 
Potential issues include: (i) supraphysiological elevations 
of GH and/or IGF1, (ii) trough GH concentrations above 
normal physiological levels, (iii) fluctuating IGF1 levels, 
(iv) elevated IGF1 in the absence of GH bioactivity, (v) 
nonphysiological tissue distribution due to distinct 
biological features of the products, and (vi) the specific 
chemical composition of each LAGH product may confer 
unique safety issues.
The impact on safety of longer exposure to GH 
and/or IGF1 with the LAGH preparations is unclear. 
Serum IGF1 levels are generally higher immediately 
following an injection and lower before the next 
injection. It will be important to associate IGF1 levels 
with side effects.
In children and adolescents, rare side effects of daily 
GH replacement include intracranial hypertension, slipped 
capital femoral epiphyses, and hyperglycemia in those 
at risk for diabetes (17). Whether LAGH will exacerbate 
these risks is unknown. The safety issues need to take into 
account specific factors including age, pubertal stage, and 
populations at risk for diabetes (particularly certain GH 
therapeutic indications such as small for gestational age 
(SGA) and Turner syndrome). In patients who develop 
the rare and serious side effect of benign intracranial 
hypertension, daily GH therapy is suspended until the 
condition resolves. One theoretical (and important) 
concern with LAGH is that the long duration of action 
does not allow immediate reversibility of exogenous GH 
exposure. In young children with congenital, severe GH 
deficiency, hypoglycemia may occur when the drug effect 
wanes. In such patients, prospective studies would need 
to include monitoring blood glucose levels at the end of 
the LAGH dosing interval, when serum GH levels may be 
at their lowest.
In children and adults, it is unclear whether 
carbohydrate or lipid metabolism (18) will differ between 
LAGH and daily GH-treated patients. Glucose metabolism 
should be monitored in patients on LAGH because of 
concerns related to the possibility of prolonged GH 
bioactivity (19).
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The theoretical concerns regarding whether there is 
an effect of GH treatment on neoplasia were addressed 
in recently published position papers (20, 21, 22). These 
concerns may also apply to LAGH. The impact of possible 
supraphysiological and sustained GH and IGF1 levels after 
an injection and the altered balance between GH and IGF1 
with LAGH on potential long-term cancer risk is unknown. 
Childhood cancer survivors should be monitored for 
possible development of secondary neoplasms, especially 
those who received cranial irradiation.
Daily administration of GH results in a consistent 
day-to-day hormonal and metabolic response (23). In 
contrast, LAGH administration may result in different 
patterns on each day within the dosing interval, and the 
long-term consequences of this pattern are unknown. It is 
important to emphasize that neither daily GH nor LAGH 
products recapitulate normal physiologic secretion.
LAGH preparations may result in injection site pain, 
skin irritation, allergic reactions, and lipoatrophy (24). 
These effects, which were reported in some early LAGH 
studies, vary among preparations (25). The incidence 
of local skin reactions for each preparation should be 
explored further.
IGF1 measurements during LAGH 
administration
Unlike the experience with daily GH, both the appropriate 
timing of blood sampling and the interpretation of the IGF1 
standard deviation score (SDS) in LAGH-treated patients 
are controversial. LAGH preparations differ in the kinetics of 
serum GH and IGF1 that they induce. Studies need to take 
into account the pharmacokinetics and pharmacodynamics 
of each product in order to gauge the optimal timing of 
IGF1 measurement. The goal is to maintain serum IGF1 
concentrations within the normal age-appropriate range for 
a majority of the treatment period.
The role of antibody measurements
Antibody measurements are used to assess potential 
immunogenicity that may impact both efficacy and 
safety. Because the impact of these antibodies on clinical 
outcomes is unclear, the interpretation of such results and 
the assimilation into study design need to be considered. 
Specifically, it is clinically important to determine whether 
there are neutralizing antibodies that could inhibit 
the intended drug effects. Discontinuation of LAGH in 
the face of rising antibody titers may be considered if there 
is a clinically significant reduction in IGF1 response or 
growth velocity or coexistence of a severe allergic reaction. 
However, there are challenges in interpreting these results 
due to the marked variability of antibody assays.
Pediatric trial design
The goals of pediatric GH therapy are to maximize adult 
height and to bring children into the normal height range 
as soon as possible. Primary outcomes include first year 
height velocity and delta height SDS (26); however, the 
most practical endpoint to measure in a Phase 3 pediatric 
clinical trial is height velocity. In addition, secondary 
outcomes include height velocity SDS, delta height 
velocity, bone age advancement, predicted adult height, 
and delta IGF1 SDS. Nongrowth outcomes should also 
be measured, including body composition, metabolic 
indices, and percentage of children entering puberty. 
Additional patient-related outcomes to be monitored 
include adherence, quality of life (QoL), and patient 
satisfaction. Models to assess burden of disease and 
therapy should be developed.
A trial duration of 1 year in prepubertal, treatment-
naïve children was considered appropriate to assess 
efficacy using a carefully matched control group. 
Longer treatment duration is required to assess the 
safety profiles of the LAGH preparations. Weight-
based fixed dosing was advised for pediatric Phase 3 
trials, with downward dose titration performed for 
elevated serum IGF1 levels demonstrated on at least 
two consecutive measurements. It is important to 
establish the appropriate time between injections for 
IGF1 measurement. Opinions differ on the utility of 
peak, mean, and trough IGF1 concentrations as tools 
to monitor and guide therapy. Phase 2 results for each 
product should provide information to determine 
which IGF1 measurement time point is clinically useful.
It is important to ensure matched study populations 
when comparing LAGH with daily GH. Variables to 
consider should include age, gender, midparental target 
height, onset of puberty, ethnicity, severity of growth 
hormone deficiency (GHD), and BMI-SDS. It will be 
essential to define selective benefits and risks of LAGH 
in randomized controlled trials in pediatric populations 
other than GHD, such as Turner syndrome, chronic renal 
failure, Prader–Willi syndrome, Noonan syndrome, short 
children born SGA, and idiopathic short stature. It should 
not be assumed that the effects and safety profile of LAGH 
in these other conditions will be similar to those seen 
with LAGH therapy in GHD.
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In clinical trials, safety monitoring should be 
performed after 1 and 3 months, and then every 3 months 
thereafter. This should include assessment of glucose 
regulation with hemoglobin A1c, fasting glucose, and 
insulin levels. Hepatic, thyroid, and adrenal function 
should also be monitored. However, in formal surveillance 
programs and clinical practice, these safety parameters 
should be considered annually.
Adult trial design
Daily GH replacement therapy for adult GHD was 
approved by the United States FDA in 1996, using changes 
in body composition as the primary outcome. Additional 
outcome measures that could be evaluated in LAGH 
trials include patient-recorded outcomes such as QoL, 
exercise capacity, and work productivity. A trial duration 
of 6 months is considered appropriate to assess efficacy. As 
in the pediatric trials, it is important to include carefully 
matched control groups. Attention should also be paid 
to the many variables previously described including 
age, gender, severity of GHD, and BMI when comparing 
LAGH with daily GH therapy. Safety of LAGH in adults 
can only be determined after a long treatment duration, 
and therefore extension studies may be required after 
completion of the controlled trials.
Truncal or visceral fat reduction at 6 months is 
recommended as the primary end point in adult trials. 
Secondary end points (some of which would require 
longer treatment duration) include IGF1, QoL, lipid 
profiles, exercise capacity, cardiovascular risk factors, and 
bone mineral density. The initial dose should take into 
account age, gender, and oral estrogen use in women. 
Study design in adults should include a dose titration to 
achieve a mean serum IGF1 in the normal age-appropriate 
range, with the timing of the IGF1 measurement based on 
pharmacodynamic findings for each compound.
Safety monitoring with laboratory tests, similar to 
those described above for the pediatric trials, should be 
performed at 1, 3, and 6 months on treatment and then at 
regular intervals (sooner if clinically indicated) in clinical 
trial extensions, formal surveillance programs, and in 
clinical practice. Brain MRI should be performed before 
the start of LAGH and as clinically indicated thereafter in 
patients with GHD due to hypothalamic–pituitary tumors.
Adherence
Adherence to therapy is an extremely important variable 
that is difficult to assess reliably. Clinical trials select 
for motivated participants and the infrastructure of 
these studies enhance adherence. Methods to monitor 
adherence include vial count, electronic devices, web-
based entry, and patient diaries. Serum IGF1 may be a 
surrogate marker of compliance. Measurement of LAGH 
by product-specific assays may be useful. Adherence may 
also be affected by ease of use of the delivery device, but 
little data are available to assess this supposition (27, 28).
Conclusion
LAGH compounds are a novel approach to the therapy of 
GHD and other growth disorders. LAGH may represent 
an advance over daily GH injections because of the 
potential for improved adherence and outcomes. LAGH 
may offer patients and families therapeutic alternatives 
and flexibility. Better methods to assess adherence need 
to be developed and validated. Long-term surveillance 
registries that include assessment of long-term efficacy, 
cost-effectiveness, disease burden, QoL, and safety 
measures are essential for understanding the impact of 
chronic exposure to all preparations of LAGH.
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